CagriSema (Cagrilintide + Semaglutide)
Semaglutide activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve glucose-dependent insulin secretion, while cagrilintide activates amylin receptors to promote satiety and slow gastric emptying. The two act through complementary appetite pathways, which is the rationale for greater weight loss from the combination than from either drug alone. Both components have multi-day half-lives that support once-weekly dosing.
Appetite or glycemic effects within the first days; full effect accrues over weeks to months alongside titration.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
According to PubMed, REDEFINE 1 (a 68-week Phase 3a trial, NCT05567796) reported an estimated mean body-weight change of -20.4% with cagrilintide-semaglutide versus -3.0% with placebo, with gastrointestinal adverse events in about 80% of the combination group, mostly transient (Garvey WT et al., N Engl J Med 2025). The earlier Phase 1b trial characterized the once-weekly pharmacokinetics supporting weekly dosing (Enebo LB et al., Lancet 2021). The combination is investigational and not yet approved.
Pharmacokinetics
- Half-life (t½)
- 7 d
- Approximate plasma half-life
- Routes
- Subcutaneous
Citations (3)
Last reviewed: 2026-06-15
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Typical Dose Range Observed
Research Protocols
Common DosagesPhase 3 target (per component)
“Reached after a multi-week titration; investigational”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Reported Uses
- Investigational once-weekly therapy for weight management in overweight or obesity
- Investigational glycemic control and weight loss in type 2 diabetes
Key Research Benefits
- Substantial weight loss in Phase 3 trials (about 20% at week 68 in REDEFINE 1)
- Greater weight loss than either component alone in the pivotal trial
- Clinically relevant glycemic improvements in type 2 diabetes settings
Potential Side Effects
Considerations and Cautions
- Personal or family history of medullary thyroid carcinoma or MEN2 (GLP-1 class)
- Hypersensitivity to either component
- History of pancreatitis (caution)
- Pregnancy
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- HbA1c: Glycemic efficacy in diabetes or at-risk users.
- Fasting glucose: Tracks glycemic response and hypoglycemia risk in combination therapy.
- Lipid panel / ApoB: Combination incretin/amylin therapy commonly improves atherogenic lipids.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 0.10 mL on a U-100 syringe
CagriSema (Cagrilintide + Semaglutide) by goal
Read CagriSema (Cagrilintide + Semaglutide)'s profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.